These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38825657)

  • 1. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade.
    Zhao L; Pang Y; Zhou Y; Chen J; Fu H; Guo W; Xu W; Xue X; Su G; Sun L; Wu H; Zhang J; Wang Z; Lin Q; Chen X; Chen H
    Signal Transduct Target Ther; 2024 Jun; 9(1):142. PubMed ID: 38825657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Evaluation of
    Galbiati A; Bocci M; Ravazza D; Mock J; Gilardoni E; Neri D; Cazzamalli S
    J Nucl Med; 2024 Oct; 65(10):1604-1610. PubMed ID: 39266289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards effective CAIX-targeted radionuclide and checkpoint inhibition combination therapy for advanced clear cell renal cell carcinoma.
    Kleinendorst SC; Oosterwijk E; Molkenboer-Kuenen J; Frielink C; Franssen GM; Boreel DF; Tamborino G; Gloudemans M; Hendrikx M; Kroon D; Hillen J; Bussink J; Muselaers S; Mulders P; Konijnenberg MW; Wheatcroft MP; Twumasi-Boateng K; Heskamp S
    Theranostics; 2024; 14(9):3693-3707. PubMed ID: 38948062
    [No Abstract]   [Full Text] [Related]  

  • 4. Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition.
    Zboralski D; Osterkamp F; Christensen E; Bredenbeck A; Schumann A; Hoehne A; Schneider E; Paschke M; Ungewiss J; Haase C; Robillard L; Simmons AD; Harding TC; Nguyen M
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(9):2621-2635. PubMed ID: 37086273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of the Tumor Stroma Using a Consensus DNA Vaccine Targeting Fibroblast Activation Protein (FAP) Synergizes with Antitumor Vaccine Therapy in Mice.
    Duperret EK; Trautz A; Ammons D; Perales-Puchalt A; Wise MC; Yan J; Reed C; Weiner DB
    Clin Cancer Res; 2018 Mar; 24(5):1190-1201. PubMed ID: 29269377
    [No Abstract]   [Full Text] [Related]  

  • 6. PET imaging facilitates antibody screening for synergistic radioimmunotherapy with a
    Ren J; Xu M; Chen J; Ding J; Wang P; Huo L; Li F; Liu Z
    Theranostics; 2021; 11(1):304-315. PubMed ID: 33391476
    [No Abstract]   [Full Text] [Related]  

  • 7. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
    Xu M; Zhang P; Ding J; Chen J; Huo L; Liu Z
    J Nucl Med; 2022 Jun; 63(6):952-958. PubMed ID: 34593598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FAP is a prognostic marker, but not a viable therapeutic target for clinical translation in HNSCC.
    Liu J; Ouyang Y; Xia Z; Mai W; Song H; Zhou F; Shen L; Chen K; Li X; Zhuang SM; Liao J
    Cell Oncol (Dordr); 2024 Apr; 47(2):623-638. PubMed ID: 37856075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization of stromal cell targeting fibroblast activation protein providing immunotherapy to breast cancer mouse model.
    Meng M; Wang W; Yan J; Tan J; Liao L; Shi J; Wei C; Xie Y; Jin X; Yang L; Jin Q; Zhu H; Tan W; Yang F; Hou Z
    Tumour Biol; 2016 Aug; 37(8):10317-27. PubMed ID: 26842926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
    Gulati P; Rühl J; Kannan A; Pircher M; Schuberth P; Nytko KJ; Pruschy M; Sulser S; Haefner M; Jensen S; Soltermann A; Jungraithmayr W; Eisenring M; Winder T; Samaras P; Tabor A; Stenger R; Stupp R; Weder W; Renner C; Münz C; Petrausch U
    Clin Cancer Res; 2018 Aug; 24(16):3981-3993. PubMed ID: 29748183
    [No Abstract]   [Full Text] [Related]  

  • 11. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [
    Arbuznikova D; Klotsotyra A; Uhlmann L; Domogalla LC; Steinacker N; Mix M; Niedermann G; Spohn SKB; Freitag MT; Grosu AL; Meyer PT; Gratzke C; Eder M; Zamboglou C; Eder AC
    Theranostics; 2024; 14(6):2560-2572. PubMed ID: 38646643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma.
    Gunderson AJ; Yamazaki T; McCarty K; Phillips M; Alice A; Bambina S; Zebertavage L; Friedman D; Cottam B; Newell P; Gough MJ; Crittenden MR; Van der Veken P; Young KH
    PLoS One; 2019; 14(2):e0211117. PubMed ID: 30726287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies.
    Fischer E; Chaitanya K; Wüest T; Wadle A; Scott AM; van den Broek M; Schibli R; Bauer S; Renner C
    Clin Cancer Res; 2012 Nov; 18(22):6208-18. PubMed ID: 22992515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma.
    Kakarla S; Chow KK; Mata M; Shaffer DR; Song XT; Wu MF; Liu H; Wang LL; Rowley DR; Pfizenmaier K; Gottschalk S
    Mol Ther; 2013 Aug; 21(8):1611-20. PubMed ID: 23732988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy.
    Nan Y; Bai Y; Hu X; Zhou K; Wu T; Zhu A; Li M; Dou Z; Cao Z; Zhang X; Xu S; Zhang Y; Lin J; Zeng X; Fan J; Zhang X; Wang X; Ju D
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39231544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting CXCR4/CXCL12 axis via [
    Bao G; Wang Z; Liu L; Zhang B; Song S; Wang D; Cheng S; Moon ES; Roesch F; Zhao J; Yu B; Zhu X
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(9):2744-2757. PubMed ID: 38587644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FAP positive fibroblasts induce immune checkpoint blockade resistance in colorectal cancer via promoting immunosuppression.
    Chen L; Qiu X; Wang X; He J
    Biochem Biophys Res Commun; 2017 May; 487(1):8-14. PubMed ID: 28302482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic Characterization of Cancer-associated Fibroblast Depletion via an Antibody-Drug Conjugate Targeting Fibroblast Activation Protein.
    Gallant JP; Hintz HM; Gunaratne GS; Breneman MT; Recchia EE; West JL; Ott KL; Heninger E; Jackson AE; Luo NY; Rosenkrans ZT; Hernandez R; Zhao SG; Lang JM; Meimetis L; Kosoff D; LeBeau AM
    Cancer Res Commun; 2024 Jun; 4(6):1481-1494. PubMed ID: 38747612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety evaluation of cross-reactive Fibroblast activation protein scFv-based CAR-T cells.
    Niu W; Wang B; Zhang Y; Wang C; Cao J; Li J; He Y; Lei P
    Front Immunol; 2024; 15():1433679. PubMed ID: 39086477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.